Showing results (11-20 of 99) with videos related to

Sort By:
Pageof 10
Drug and Alcohol Dependence|May 23, 2007
Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadoneJames Rosado, Sharon L Walsh, George E Bigelow, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 7, 2011
Discriminative stimulus effects of tramadol in humansAngela N Duke, George E Bigelow, Ryan K Lanier, et al.
JAMA Psychiatry|July 13, 2017
Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical TrialKelly E Dunn, D Andrew Tompkins, George E Bigelow, et al.
Psychopharmacology|October 3, 2006
Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h periodChristopher J Correia, Sharon L Walsh, George E Bigelow, et al.
Journal of Consulting and Clinical Psychology|October 16, 2004
A randomized trial of long-term reinforcement of cocaine abstinence in methadone-maintained patients who inject drugsKenneth Silverman, Elias Robles, Timothy Mudric, et al.
Addiction (Abingdon, England)|February 28, 2006
An injection depot formulation of buprenorphine: extended bio-delivery and effectsStacey C Sigmon, David E Moody, Elie S Nuwayser, et al.
Drug and Alcohol Dependence|February 2, 2013
Opioid abusers' ability to differentiate an opioid from placebo in laboratory challenge testingDenis G Antoine, Eric C Strain, D Andrew Tompkins, et al.
The American Journal on Addictions|July 31, 2007
Experimentally-induced spontaneous opiate withdrawal: relationship to cigarette craving and expired air carbon monoxideMichelle R Lofwall, Sharon L Walsh, George E Bigelow, et al.
Journal of Substance Abuse Treatment|September 1, 2009
Measurement of self-reported HIV risk behaviors in injection drug users: comparison of standard versus timeline follow-back administration proceduresMarc L Copersino, Christina S Meade, George E Bigelow, et al.
Pageof 10